コンテンツへスキップ
Merck
  • Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis.

Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis.

Cancer cell (2020-01-15)
Douglas Hanniford, Alejandro Ulloa-Morales, Alcida Karz, Maria Gabriela Berzoti-Coelho, Rana S Moubarak, Beatriz Sánchez-Sendra, Andreas Kloetgen, Veronica Davalos, Jochen Imig, Pamela Wu, Varshini Vasudevaraja, Diana Argibay, Karin Lilja, Tommaso Tabaglio, Carlos Monteagudo, Ernesto Guccione, Aristotelis Tsirigos, Iman Osman, Iannis Aifantis, Eva Hernando
要旨

Metastasis is the primary cause of death of cancer patients. Dissecting mechanisms governing metastatic spread may uncover important tumor biology and/or yield promising therapeutic insights. Here, we investigated the role of circular RNAs (circRNA) in metastasis, using melanoma as a model aggressive tumor. We identified silencing of cerebellar degeneration-related 1 antisense (CDR1as), a regulator of miR-7, as a hallmark of melanoma progression. CDR1as depletion results from epigenetic silencing of LINC00632, its originating long non-coding RNA (lncRNA) and promotes invasion in vitro and metastasis in vivo through a miR-7-independent, IGF2BP3-mediated mechanism. Moreover, CDR1as levels reflect cellular states associated with distinct therapeutic responses. Our study reveals functional, prognostic, and predictive roles for CDR1as and expose circRNAs as key players in metastasis.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
モノクロナール抗α-チューブリン マウス宿主抗体, clone DM1A, ascites fluid
Sigma-Aldrich
抗ウサギIgG (全分子)-ペルオキシダーゼ ヤギ宿主抗体, affinity isolated antibody
Sigma-Aldrich
抗βアクチン−ペルオキシダーゼ抗体、マウスモノクローナル マウス宿主抗体, clone AC-15, purified from hybridoma cell culture
Sigma-Aldrich
抗マウスIgG (全分子)-ペルオキシダーゼ ウサギ宿主抗体, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
MISSION® esiRNA, targeting human CD44
Sigma-Aldrich
MISSION® esiRNA, targeting human IGF2BP3
Sigma-Aldrich
MISSION® esiRNA, targeting human HAS2
Sigma-Aldrich
MISSION® esiRNA, targeting human MEF2C
Sigma-Aldrich
MISSION® esiRNA, targeting human GAS7
Sigma-Aldrich
MISSION® esiRNA, targeting human SEMA6D
Sigma-Aldrich
MISSION® esiRNA, targeting human SNAI2